ClinicalTrials.gg
Active, not recruitingNCT06824987APPRECIATEUpdated Oct 13, 2026

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

A Phase 2 interventional study of AZD2373-Arm 1 and AZD2373-Arm 2 in APOL1-Mediated Kidney Disease, sponsored by AstraZeneca. Active, not recruiting at 96 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Updated Oct 13, 2026Enrollment updated33 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.

Read the detailed description

This is a Phase 2b study to assess efficacy and safety of AZD2373 involving 3 study treatment arms in Part A and 2 study treatment arms in Part B where participants and study personnel including study investigators are blinded to the assigned treatment.

Participants with 300 mg/g or greater UACR and eGFR ≥ 25mL/min/1.73m2 will be recruited into the study. Participants on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant will be excluded.

The study will have Part A and Part B. Part A (n = 96) will have a 1:1:1 randomization of participants to subgroups receiving weekly subcutaneous injections of 50 mg AZD2373, 150 mg AZD2373, and placebo. Part B (n = 40) will have a 4:1 randomization of participants to subgroups receiving every other week subcutaneous injections of 150 mg or placebo. Part B will begin after Part A is completely enrolled.

Both Part A and Part B will have same participant criteria and schedules. The SoA and visit schedule will not change for Part B.

All participants will remain in the study on treatment until the last participant has completed 30 weeks of treatment. The treatment duration will be up to minimum of 30 weeks of study treatment.

All participants will have the opportunity to enter the OLE study.

02

Conditions studied

  • APOL1-Mediated Kidney Disease

Keywords

  • APOL1-Mediated Kidney Disease
  • AZD2373
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Male and female participants of African descent (including, but not limited to, Black, Black African, Black Caribbean, African American, Afro-Caribbean, Afro-Latino, West African, Mixed Black backgrounds, or other self-identified African diaspora heritage) aged 18 to 70 years, inclusive at the time of .
  • Participants who have high-risk APOL1 genotype (G1/G1; G1/G2; G2/G2). The screening period can be extended if there are delays related to the shipment, handling, or processing of genotype results.
  • A geometric mean UACR ≥ 300 mg/g calculated based on the mean of readings taken from 3 FMV urine samples collected on 3 consecutive days. Since the mean will be assessed for eligibility, any of the 3 readings may fall below 300 mg/g.
  • ≥ 25 mL/min/1.73m2.
  • use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Participants with diagnosis of Type 1 diabetes mellitus.
  • > 45 kg/m2.
  • SBP > 180 mmHg/DBP > 110 mmHg (measured when the participant is considered to be at steady state, and preferably when they have taken their BP medications that same day).
  • > 470 ms, except participants with bundle branch block who should excluded if QTcF> 480 ms.
  • Acute coronary syndrome/Acute myocardial infraction with or without any coronary intervention within 6 months.
  • / stroke within 3 months.
  • High grade (second to third) degree AV block or sinus node dysfunction untreated with pacemaker.
  • A history of ventricular arrhythmias requiring treatment.
  • Participants with Type 2 diabetes mellitus must be excluded if ANY of the following conditions are present:

    1. Current or past use of insulin for more than 3 months and/or any maintenance therapy with insulin within 2 months of screening.
    2. Screening > 8.0%
    3. Receiving more than one anti-hyperglycaemic agent (excluding SGLT inhibitors and GLP-1 receptor agonists is permitted if prescribed for a purpose other than glycaemic control which can be taken in addition to one other anti-hyperglycaemic agent).
  • Participant on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant.
  • History or serologic evidence of -mediated glomerular disease including but not limited to: lupus nephritis (positive lupus serology), ANCA associated vasculitis (antineutrophil cytoplasmic antibody), membranous nephropathy (anti-phospholipase A2 receptor antibody or other autoantibody associated with membranous nephropathy), anti-GBM disease (anti-GBM antibody), or IgA nephropathy.
  • Another underlying cause of kidney disease that is not associated with APOL1, including but not limited to polycystic kidney disease or, congenital anomalies of the kidney and urinary tract.
  • History of a diagnosed coagulopathy, a major unexplained bleeding event, or other high-risk bleeding diathesis.
  • A history of trypanosomiasis or leishmaniasis.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Placebo comparator
    Part A - Placebo group

    Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose.

    Combination Product: Placebo · Device: APOL1 Genotyping Clinical Trial Assay

  • Experimental
    Part A - AZD2373 - Arm 1

    Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose.

    Combination Product: AZD2373-Arm 1 · Device: APOL1 Genotyping Clinical Trial Assay

  • Experimental
    Part A - AZD2373 - Arm 2

    Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose.

    Combination Product: AZD2373-Arm 2 · Device: APOL1 Genotyping Clinical Trial Assay

  • Experimental
    Part B - AZD2373 Arm 1

    Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose

    Combination Product: AZD2373-Arm 2 · Device: APOL1 Genotyping Clinical Trial Assay

  • Placebo comparator
    Part B - Placebo group

    Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose

    Combination Product: Placebo · Device: APOL1 Genotyping Clinical Trial Assay

Interventions

  • Combination productAZD2373-Arm 1

    Accessorized Pre-Filled Syringe (Solution for injection)

  • Combination productAZD2373-Arm 2

    Accessorized Pre-Filled Syringe (Solution for injection)

  • Combination productPlacebo

    Accessorized Pre-Filled Syringe (Solution for injection).

  • DeviceAPOL1 Genotyping Clinical Trial Assay

    The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.

06

What researchers measure

Primary outcomes

  1. Relative change in Urine Albumin-Creatinine Ratio (UACR)

    To assess the effect of AZD2373 versus placebo in reducing albuminuria

    Time frame: From Baseline at Week 30

Secondary outcomes

  1. Relative change in Urine Albumin-Creatinine Ratio (UACR)

    To assess the effect of AZD2373 versus placebo in reducing albuminuria

    Time frame: From Baseline at the End of Treatment (Until the last participant completes Week 30)

  2. Relative change in Urine Protein-Creatinine Ratio (UPCR)

    To assess the effect of AZD2373 versus placebo in reducing proteinuria

    Time frame: From Baseline at Week 30

  3. Relative change in Urine Protein-Creatinine Ratio (UPCR)

    To assess the effect of AZD2373 versus placebo in reducing proteinuria

    Time frame: From Baseline at the End of Treatment (Until the last participant completes Week 30)

  4. Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)

    To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment

    Time frame: From Baseline at Week 30

  5. Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)

    To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment

    Time frame: From Baseline at the End of Treatment (Until the last participant completes Week 30)

  6. eGFR slope

    To assess pooled AZD2373 doses versus placebo on eGFR change

    Time frame: From Baseline at the End of Treatment (Until the last participant completes Week 30)

  7. Incidence of development of ADA and ADA titer (if participants are ADA-positive)

    To evaluate the immunogenicity of AZD2373

    Time frame: During treatment (up to Week 30) and follow-up (up to 12 weeks)

  8. Plasma concentration

    To evaluate the PK of AZD2373

    Time frame: From Baseline at the End of Treatment (Until the last participant completes Week 30)

  9. Adverse Events (AEs), Serious Adverse Events (SAEs), and Drug Adverse Events (DAEs).

    To assess the safety and tolerability of ranging doses of AZD2373. These events will be collected according to the timepoints specified in the schedule of assessments, starting from the time of signing the Informed Consent Form (ICF).

    Time frame: From baseline at the End of Treatment (Until the last participant completes Week 30)

07

Study locations

96 sites
  • Research Site
    Alabaster, Alabama 35007, United States
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Irondale, Alabama 35210, United States
  • Research Site
    Surprise, Arizona 85374, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Concord, California 94520, United States
  • Research Site
    Fremont, California 94538, United States
  • Research Site
    Gardena, California 90247, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Valencia, California 91355, United States
  • Research Site
    Boca Raton, Florida 33487, United States
  • Research Site
    Brandon, Florida 33511, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Orlando, Florida 32808, United States
  • Research Site
    Pompano Beach, Florida 33060, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Augusta, Georgia 30904, United States
  • Research Site
    Augusta, Georgia 30909, United States
  • Research Site
    Augusta, Georgia 30912, United States
  • Research Site
    Columbus, Georgia 31901, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Duluth, Georgia 30096, United States
  • Research Site
    Hinesville, Georgia 31313, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Macon, Georgia 31210, United States
  • Research Site
    Macon, Georgia 31217, United States
  • Research Site
    Marietta, Georgia 30067, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Stockbridge, Georgia 30281, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Chicago, Illinois 60643, United States
  • Research Site
    Hinsdale, Illinois 60521, United States
  • Research Site
    Rockford, Illinois 61107, United States
  • Research Site
    Baton Rouge, Louisiana 70808, United States
  • Research Site
    Lafayette, Louisiana 70508, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Shreveport, Louisiana 71103, United States
  • Research Site
    Bethesda, Maryland 20889, United States
  • Research Site
    Potomac, Maryland 20854, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Worcester, Massachusetts 01608, United States
  • Research Site
    Lansing, Michigan 48911, United States
  • Research Site
    Roseville, Michigan 48066, United States
  • Research Site
    Minneapolis, Minnesota 55455, United States
  • Research Site
    Columbus, Mississippi 39705, United States
  • Research Site
    Tupelo, Mississippi 38801, United States
  • Research Site
    Brooklyn, New York 11203, United States
  • Research Site
    Brooklyn, New York 11221, United States
  • Research Site
    Laurelton, New York 11413, United States
  • Research Site
    New York, New York 10010, United States
  • Research Site
    Rockville Centre, New York 11570, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    Cary, North Carolina 27511, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Fayetteville, North Carolina 28304, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Jacksonville, North Carolina 28546, United States
  • Research Site
    Kinston, North Carolina 28501, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Cincinnati, Ohio 45246, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Bridgeville, Pennsylvania 15017, United States
  • Research Site
    Butler, Pennsylvania 16001, United States
  • Research Site
    Exton, Pennsylvania 19341, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Anderson, South Carolina 29621, United States
  • Research Site
    Columbia, South Carolina 29203, United States
  • Research Site
    Orangeburg, South Carolina 29118, United States
  • Research Site
    Spartanburg, South Carolina 29306, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Conroe, Texas 77304, United States
  • Research Site
    Conroe, Texas 77384, United States
  • Research Site
    Dallas, Texas 75234, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77054, United States
  • Research Site
    Katy, Texas 77450, United States
  • Research Site
    Mesquite, Texas 75149, United States
  • Research Site
    Pearland, Texas 77584, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    Norfolk, Virginia 23510, United States
  • Research Site
    Portsmouth, Virginia 23708, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Birmingham, B15 2WB, United Kingdom
  • Research Site
    Leicester, Le5 4PW, United Kingdom
  • Research Site
    Liverpool, L22 0LG, United Kingdom
  • Research Site
    London, NW3 2QG, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    London, SE5 8AZ, United Kingdom
  • Research Site
    London, SM5 1AA, United Kingdom
  • Research Site
    London, SW17 0QT, United Kingdom
  • Research Site
    London, SW7 2AZ, United Kingdom
  • Research Site
    Manchester, M13 9WL, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Feb 13, 2025
StartActual
Mar 5, 2025
Primary completionEst.
Oct 4, 2027
CompletionEst.
Oct 4, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
33 sites added
Show 33 added (29 United States, 4 United Kingdom)
  • Research Site · Birmingham, United States
  • Research Site · Gardena, United States
  • Research Site · Los Angeles, United States
  • Research Site · Valencia, United States
  • Research Site · Brandon, United States
  • Research Site · Miami, United States
  • Research Site · Augusta, United States
  • Research Site · Columbus, United States
  • Research Site · Hinesville, United States
  • Research Site · Savannah, United States
  • Research Site · Hinsdale, United States
  • Research Site · Worcester, United States
  • Research Site · Lansing, United States
  • Research Site · Brooklyn, United States
  • Research Site · Brooklyn, United States
  • Research Site · Laurelton, United States
  • Research Site · Rockville Centre, United States
  • Research Site · Greenville, United States
  • Research Site · Kinston, United States
  • Research Site · Butler, United States
  • Research Site · Anderson, United States
  • Research Site · Chattanooga, United States
  • Research Site · Dallas, United States
  • Research Site · Katy, United States
  • Research Site · Mesquite, United States
  • Research Site · Pearland, United States
  • Research Site · San Antonio, United States
  • Research Site · Norfolk, United States
  • Research Site · Portsmouth, United States
  • Research Site · Leicester, United Kingdom
  • …and 3 more on the registry record
Oct 13, 2026
Enrollment
57→63
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    33 sites added
    Show 33 added (29 United States, 4 United Kingdom)
    • Research Site · Birmingham, United States
    • Research Site · Gardena, United States
    • Research Site · Los Angeles, United States
    • Research Site · Valencia, United States
    • Research Site · Brandon, United States
    • Research Site · Miami, United States
    • Research Site · Augusta, United States
    • Research Site · Columbus, United States
    • Research Site · Hinesville, United States
    • Research Site · Savannah, United States
    • Research Site · Hinsdale, United States
    • Research Site · Worcester, United States
    • Research Site · Lansing, United States
    • Research Site · Brooklyn, United States
    • Research Site · Brooklyn, United States
    • Research Site · Laurelton, United States
    • Research Site · Rockville Centre, United States
    • Research Site · Greenville, United States
    • Research Site · Kinston, United States
    • Research Site · Butler, United States
    • Research Site · Anderson, United States
    • Research Site · Chattanooga, United States
    • Research Site · Dallas, United States
    • Research Site · Katy, United States
    • Research Site · Mesquite, United States
    • Research Site · Pearland, United States
    • Research Site · San Antonio, United States
    • Research Site · Norfolk, United States
    • Research Site · Portsmouth, United States
    • Research Site · Leicester, United Kingdom
    • …and 3 more on the registry record
    Enrollment 57→63
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06824987
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Mar 5, 2025
Primary completion
Oct 4, 2027 (estimated)
Completion
Oct 4, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opemalirsen

Start the discussion